Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results